| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.0091 | 0.9 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0048 | 0.9 |
| mRNA | PF-750 | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | 0.006 | 0.9 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | BRD-K20514654 | CTRPv2 | pan-cancer | AAC | 0.0054 | 0.9 |
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |